NDA 021396 · Wyeth Ayerst
Prempro/Premphase
Conjugated Estrogens/Medroxyprogesterone Acetate · Oral
Last checked: Nov 20, 2026Latest source record: Jun 4, 2003 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2003
Jun 4, 2003
Approved uses
1
Original approval plus efficacy supplements
Registered trials
17
9 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 4, 2003 Original approval · Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval LabelReviewLetter
1 products under this application
- PREMPRO/PREMPHASE · CONJUGATED ESTROGENS/MEDROXYPROGESTERONE ACETATE 0.45MG/1.5MG & 0.3MG/1.5MG · Tablet, Oral · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Conjugated Estrogens/Medroxyprogesterone" as an intervention, any sponsor and status, largest first.
- Heart and Estrogen-Progestin Replacement Study (HERS)Pivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT00319566 · 2,430 participants · Start Jul 1992
Drug: Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily · For: Coronary Heart Disease
Sites: San Francisco, California
- Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal OsteoporosisPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00808132 · 1,886 participants · Start Jan 2009 · Primary completion Feb 2011
Drug: bazedoxifene 20 mg/ conjugated estrogens 0.45 mg; bazedoxifene 20 mg/ conjugated estrogens 0.625 mg and 3 more · For: Menopause; Osteoporosis
Sites: Birmingham, Alabama; Mobile, Alabama; Chandler, Arizona · 178 sites in all
- Herbal Alternatives for Menopause Symptoms (HALT Study)Pivotal-lookingStatus unknown
Kaiser PermanenteAcademic, hospital or other
NCT00169299 · 351 participants · Start Jun 2001
Drug: Black cohosh; Multibotanical preparation and 2 more · For: Vasomotor Symptoms Associated With Menopause
Sites: Seattle, Washington
- Safety of Estrogens in Lupus: Hormone Replacement TherapyPivotal-lookingTerminated
NYU Langone HealthAcademic, hospital or other
NCT00000419 · 350 participants · Start Apr 1996
Drug: Premarin and Provera · For: Systemic Lupus Erythematosus
Sites: Birmingham, Alabama; Los Angeles, California; Chicago, Illinois · 16 sites in all
- The Estrogen Replacement and Atherosclerosis Trial ; Primary Outcome Measure is Mean Minimal Coronary Artery Diameter After Avg of 3.2 Yrs.Pivotal-lookingCompleted
Wake Forest University Health SciencesAcademic, hospital or other
NCT03097120 · 309 participants · Start Jan 1995 · Primary completion Jan 2001
Drug: 0.625 mg of conjugated equine estrogen; 0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate and 1 more · For: Heart Disease
Sites: Winston-Salem, North Carolina
- Estrogen, HDL, and Coronary Heart Disease in WomenPivotal-lookingCompleted
Tufts UniversityAcademic, hospital or other
NCT00083824 · 309 participants · Start Mar 2004 · Primary completion Feb 2007
Drug: Estrogens, Conjugated (USP); Medroxyprogesterone 17-Acetate and 1 more · For: Cardiovascular Diseases; Coronary Disease; Heart Diseases and 1 more
Sites: Boston, Massachusetts
- Phase III Randomized Study of the Effect of Postmenopausal Estrogen Replacement Therapy on Alveolar Bone LossPivotal-lookingCompleted
National Institute of Dental and Craniofacial Research (NIDCR)NIH
NCT00004650 · 150 participants · Start Aug 1993
Drug: conjugated estrogens; Medroxyprogesterone · For: Osteoporosis
- Hormone Replacement in Menopausal Women With EpilepsyPivotal-lookingCompleted
National Institute of Neurological Disorders and Stroke (NINDS)NIH
NCT00027209 · 125 participants
Drug: prempro · For: Menopause; Epilepsy
Sites: New York, New York
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial.
Pinkerton JV, Harvey JA, Pan K, et al. · Obstet Gynecol 2013 · Clinical Trial, Phase III, Multicenter Study
- Changes in normal lipid profile of menopausal women with combined hormone replacement therapy. Comparative clinical trial of two hormonal combinations (conjugated estrogens/medroxyprogesterone acetate versus estradiol valerate/cyproterone acetate).
Alwers R, Urdinola J, Onatra W, et al. · Maturitas 1999 · Clinical Trial, Clinical Trial, Phase III
- Vaginal bleeding/spotting with conjugated estrogens/bazedoxifene, conjugated estrogens/medroxyprogesterone acetate, and placebo.
Kagan R, Abreu P, Andrews E · Postgrad Med 2018 · Clinical Trial, Phase III, Multicenter Study
- Metabolic effect of two hormonal preparations in postmenopausal women.
Bissonnette F, Lussier-Cacan S, Fugère P, et al. · Maturitas 1997 · Clinical Trial, Comparative Study
- Gynecologic Safety of Conjugated Estrogens Plus Bazedoxifene: Pooled Analysis of Five Phase 3 Trials.
Mirkin S, Pinkerton JV, Kagan R, et al. · J Womens Health (Larchmt) 2016 · Randomized Controlled Trial
- [Differential effects on serum IGF-1 of tibolone (5 mg/day) vs combined continuous estrogen/progestagen in post menopausal women].
Porcile A, Gallardo E, Duarte P, et al. · Rev Med Chil 2003 · Clinical Trial, Comparative Study
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.